Sr. Associate Director of Licensing, Office of Cooperative Research, Yale University
David Lewin, Ph.D., is Sr. Associate Director of Licensing for Yale University’s Office of Cooperative Research (“OCR”), which is the technology transfer office for Yale. His responsibilities in this role encompass primarily life science technology evaluation, intellectual property management, technology marketing, licensing strategy and negotiation, and management of relationships with commercial partners; he joined OCR in 2005. Recently, he was a recipient, along with his colleagues at Oncolys Biopharma, a Japanese biotechnology company, and Bristol-Meyers Squibb, of the Licensing Executives Society 2011 Deals of Distinction Award for their efforts to commercialize a Yale-invented HIV/AIDS treatment, festinavir. Prior to coming to OCR, Lewin was a group leader at a Connecticut biotechnology company, CuraGen Corporation, where he was responsible for managing hte business and scientific relationships between CuraGen and its genomics/proteomics discovery partners Genentech, Roche, Alexion, Mitsubishi, and others. He subsequently led a biomarket discovery and development project group that implemented clinical biomarkers for CuraGen’s protein therapeutic velafirmin, a candidate treatment for oral mucusitis. Lewin joined CuraGen in 1997 after receiving his Ph.D. from the Department of Cell Biology at Yale University; he holds a B.A. in biochemistry and cell biology from the University of California, San Diego.